What Is PAH Life Expectancy and Survival Rate Today?

If you have just searched for the life expectancy of pulmonary arterial hypertension (PAH), you have likely found some terrifying numbers. The most important thing to know is that many of those statistics are decades out of date and reflect an era before modern treatments existed. In the 1980s, the 3-year survival rate for idiopathic PAH was around 48% ^[1]. Today, outcomes have improved significantly for patients receiving care at specialized centers. In modern registries, groups of younger patients with “classical” idiopathic PAH have shown survival rates around 95% at one year and 84% at five years ^[2]. However, these numbers are population averages from specific observational studies, not an individual forecast or a guarantee. Your personal prognosis depends heavily on your age, other health conditions, and how your body responds to modern therapies.

Important Safety Note: Do not start, stop, or change your PAH medications based on online statistics. Abruptly stopping certain medications, particularly intravenous or subcutaneous therapies (prostacyclins), can be life-threatening. Seek urgent medical attention if you experience worsening breathlessness, fainting, chest pain, or rapidly increasing swelling.

Understanding the Medical Terms

When reading about survival rates, it helps to understand the terminology used in the registries:

• Group 1 PAH: A specific medical classification that includes idiopathic PAH (unknown cause) and heritable PAH (genetic cause), as well as PAH caused by connective tissue diseases, toxins, or congenital heart defects.
• Classical Idiopathic PAH: Typically refers to younger patients who do not have significant other health conditions (comorbidities) like heart disease, lung disease, or a history of heavy smoking.
• Phenotype: The observable characteristics of a patient (such as their age, lung function, and other illnesses).

The Shift from the 1980s Untreated Era

The most frequently cited—and most frightening—numbers online often originate from the original National Institutes of Health (NIH) Primary Pulmonary Hypertension Registry from 1980 to 1985 ^[1]. During that time, there were no targeted PAH medications. The historical median survival in that untreated era was just 2.8 years, and the 3-year survival rate was 48% ^[3][1]. These historical estimates describe what the disease looked like before the modern treatment era, not what you should expect today.

What Modern Registries Actually Show

Doctors use modern registries—large databases tracking current patients—to understand how people are doing on newer therapies. However, survival rates from different registries cannot be directly compared because they track different types of patients over different years.

• Treated Idiopathic/Heritable Cohorts: In a Japanese registry of patients treated for idiopathic or heritable PAH between 1992 and 2012, observed survival rates from treatment initiation were 97.9% at 1 year, 92.1% at 3 years, 85.8% at 5 years, and 69.5% at 10 years ^[4].
• COMPERA Registry: In this European registry, patients categorized as having “classical” idiopathic PAH showed an 84% survival rate at 5 years ^[2]. However, within the same registry, older patients with a history of smoking or multiple other health conditions had a 5-year survival closer to 42% to 59% ^[5].
• REVEAL and Swedish Registries: When a registry includes all forms of Group 1 PAH and older patients with more health issues, the average survival drops. The US-based REVEAL registry showed an average 5-year survival of 61.2% to 65.4% ^[6]. A Swedish registry with older, more complex patients reported a 5-year survival of 59% ^[7].

These numbers show that an “average” statistic cannot describe every person. Age and other health conditions heavily impact these figures ^[8].

How Modern Therapy is Used Today

The improvements seen in modern registries are closely tied to how doctors use targeted medications. However, treatment is highly individualized by a pulmonary hypertension specialist.

• Upfront Combination Therapy: Instead of starting with one medication, doctors now commonly prescribe two oral targeted drugs at the same time for newly diagnosed patients at low or intermediate risk ^[9]. Common combinations include an endothelin receptor antagonist (a drug that blocks a substance that narrows blood vessels) and a PDE5 inhibitor (a drug that helps blood vessels relax and widen). This approach has been shown to reduce the risk of clinical failure ^[10].
• Triple Therapy for High-Risk Disease: For patients with severe or high-risk disease, initial triple therapy that includes a prostacyclin (a powerful continuous medication given via IV or beneath the skin) may be urgently considered. One observational study noted a 10-year survival of 85% with initial triple therapy versus 65% with initial dual therapy ^[11]. It is important to note that this is an observational association, not proof that triple therapy causes superior survival in everyone; treatment choices depend heavily on a patient’s baseline severity and ability to manage complex infusion pumps.
• Disease-Modifying Add-On Drugs: Sotatercept is a newer add-on medication that targets the underlying pathway of cell growth in the blood vessels. In clinical trials, it improved exercise capacity (how far patients can walk) and reduced clinical worsening events ^[12][13]. Because it is relatively new, an independent long-term survival benefit is still being studied, so we do not yet have 10-year survival data for it ^[14]. It is prescribed by specialists and requires monitoring for potential side effects, such as changes in blood counts and increased bleeding risk.

Your Risk Status: A Better Guide than Averages

Instead of relying on online averages, your specialist will calculate your risk status using modern guideline frameworks (like COMPERA 2.0 or REVEAL Lite 2). This assessment looks at multiple factors:

• Your symptoms and WHO functional class (how much physical activity you can do).
• A 6-minute walk distance test.
• Blood tests like BNP or NT-proBNP (markers of heart strain).
• Echocardiograms (ultrasound of the heart) and sometimes a right heart catheterization (a procedure to measure internal blood pressures).

These tools categorize your disease as low, intermediate-low, intermediate-high, or high risk ^[15][16]. The goal of therapy is to help you achieve and maintain a “low risk” status. While achieving a low-risk category is a probabilistic target rather than a guarantee of long-term survival, it is currently the best way your care team can estimate your personal prognosis and adjust your treatments accordingly.